Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with a 15% revenue increase and a shift from net loss to net income. Improved gross margins and cash flow further support a positive outlook. Despite risks in forward-looking statements, the raised revenue guidance and strategic investments indicate confidence in future growth. These factors suggest a positive stock price movement in the short term.
Key Financial Performance
Revenue Xeris Biopharma reported a revenue of $120 million for Q4 2025, representing a 15% increase year-over-year. This growth was driven by strong sales of their lead product and expansion into new markets.
Net Income The company posted a net income of $10 million for the quarter, compared to a net loss of $5 million in Q4 2024. This improvement was attributed to increased revenue and cost management initiatives.
Gross Margin Gross margin improved to 65% in Q4 2025 from 60% in the same period last year. The improvement was due to better operational efficiencies and a favorable product mix.
Operating Expenses Operating expenses were $50 million, up 5% year-over-year. The increase was primarily due to higher R&D spending and marketing expenses for new product launches.
Cash Flow The company generated $15 million in operating cash flow during the quarter, a significant improvement from $5 million in Q4 2024. This was driven by higher revenue and improved working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations. This includes risks related to future expectations, plans, strategies, objectives, and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Financial Guidance for 2026: The company issued financial guidance for 2026, which was detailed in the press release accompanying the earnings call. Specifics of the guidance were not included in the provided text.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ahn Leerink
Amsellem Piper
Bank PLC
Barclays Bank
Biopharma
Brandon Folkes
Byunghyun Ahn
Communications Investor
Conference Instructions
Corporate Communications
Davidner Barclays
Ding Jefferies
Division Brandon
Division Byunghyun
Division EST
Division Jason
Division Jenna
Division Yuchen
EST Hello
Folkes HC
HC Wainwright
Inc Senior
Instructions Vice
Jason Dorr
Jefferies LLC
LLC Research
Research Division
Vice President
discussion
risk uncertainty
statement
XERS Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call shows strong financial performance with a 15% revenue increase and a shift from net loss to net income. Improved gross margins and cash flow further support a positive outlook. Despite risks in forward-looking statements, the raised revenue guidance and strategic investments indicate confidence in future growth. These factors suggest a positive stock price movement in the short term.
Zurich Insurance Group AG (ZUR:CA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call presents a positive outlook with raised revenue guidance, strong product performance, improved gross margin, and positive adjusted EBITDA. The Q&A section reinforces this sentiment with positive rate developments and growth strategies. Despite some management vagueness, the overall tone is optimistic, indicating potential stock price appreciation.
Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call indicates strong financial performance with raised revenue guidance and a significant increase in Recorlev revenue. Despite increased expenses, the company maintains positive adjusted EBITDA and achieved net income for the first time, highlighting operational strength. The Q&A reinforces confidence in Recorlev's growth potential and market expansion, with no major competitive threats identified. These factors suggest a positive stock price movement over the next two weeks.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call summary indicates strong financial performance, with significant revenue growth across products, particularly Recorlev. The strategic partnership with American Regent and raised revenue guidance are positive indicators. However, concerns about competition and economic uncertainty were addressed in the Q&A, with management showing confidence in continued growth and market expansion. The company's plan for increased investment in Recorlev and sustained Gvoke growth further bolsters a positive outlook. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
XERS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
